Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.
about
The Contribution of Advanced Glycation End product (AGE) accumulation to the decline in motor functionAdvanced glycated end-products affect HIF-transcriptional activity in renal cellsPlasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failureSkin autofluorescence and all-cause mortality in stage 3 CKD.Association of insulin-related serum factors with colorectal polyp number and type in adult males.Novel Inhibitory Effects of Glycyrrhizic Acid on the Accumulation of Advanced Glycation End Product and Its Receptor Expression.Novel insights into the relationship between diabetes and osteoporosisMicroalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis PatientsSkin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway.Low Bone Mass is Associated with Increased Carotid Intima Media Thickness in Men with Type 2 Diabetes Mellitus.Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study.Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndromeFetuin-A and angiopoietins in obesity and type 2 diabetes mellitus.Diabetes mellitus and osteoporosis.Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease.Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an in-vitro model of human proximal tubular epithelial cells.Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) studyIs Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.Perspectives on RAGE signaling and its role in cardiovascular disease.High plasma level of soluble RAGE is independently associated with a low recurrence of atrial fibrillation after catheter ablation in diabetic patient.Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease.Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.
P2860
Q26767495-0578E34E-C899-439A-BF09-F81E4D230243Q28591845-D29B3469-D5D8-4714-B3CF-04505D705101Q33810217-6912FEB3-031A-43C8-9435-BC7132E8E55BQ34008927-CB0F4378-140E-454C-B4B0-816CDD11C2D8Q34135535-31BFA8F5-D8DC-45AE-9FC2-BA92969D6E91Q34604583-80784C6C-3441-45CF-ACF0-35F68DAEB304Q35674683-C573EC05-2786-4F53-B85B-827CFD6FEDA3Q35837912-F7871611-BDE1-4A99-B517-16748B24C839Q35882416-94628EB1-8770-4691-BDBE-FE33024E9399Q35935760-D1AB0FA8-284D-425B-9BC1-94899CB20224Q35985860-1CBFF41F-24B5-48F5-A029-2B4AC2E7985FQ36321887-85598B0A-7DDD-4D34-9DF8-4EBBDA422109Q36929402-B2F4D5A1-94E3-4C89-A7B2-5D24D4511D02Q37113344-9F898B2F-A605-4E9F-A8B2-86D673BB594DQ37235902-0E937443-BE33-401E-B8E7-C3E72B6B21DCQ37831838-1FD1BBC3-E7D6-4EDE-BC96-493C348A7702Q38028344-8284900A-613E-4D99-8301-94493B0FBB8BQ38087556-A624F47B-6F99-467D-A4AF-5439052BF1C2Q38370045-AC95A1D9-A246-49F3-BEB7-138C3000738FQ38651423-9B9524A6-DA4A-4B6E-8290-E28C5D37518CQ39027326-7EF98A39-F23A-4C33-B071-69599D5387FEQ39190228-A61270E0-786A-4302-AD51-77D2048FF679Q41702511-DF729E68-E0CF-48BF-8C1C-AC462E08C92EQ41975172-705A03CD-38A5-4ED6-96F4-8F017DBD5FA2Q51325589-E118CC49-17A0-4752-919E-CFC29A814EC1Q53344878-B032A5E6-AF4D-420F-9460-446BD670659DQ53762692-5A536C0F-ECC8-44F9-82D3-ECAE2F956FD2Q54605224-69C8E0AC-FE84-4DD5-8625-F9236E39630DQ55474587-EB85AC82-A86F-4099-BBF0-97467F616267
P2860
Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Receptor for advanced glycatio ...... : cardiovascular implications.
@en
type
label
Receptor for advanced glycatio ...... : cardiovascular implications.
@en
prefLabel
Receptor for advanced glycatio ...... : cardiovascular implications.
@en
P2093
P2860
P356
P1476
Receptor for advanced glycatio ...... ): cardiovascular implications
@en
P2093
Darren K McGuire
Jason B Lindsey
Shuaib M Abdullah
P2860
P356
10.3132/DVDR.2009.002
P407
P577
2009-01-01T00:00:00Z